Match tier
Listed
Presence
Current · Arkansas
Last published
2025
Sources
OpenAlex · ORCID
Refreshed
2026-08-08
Biography and Research Information
OverviewAI-generated summary
Gunaganti Naresh's research focuses on the discovery and chemical optimization of novel therapeutic agents. His work has involved the development of compounds targeting specific molecular pathways implicated in disease. He has investigated potential treatments for Human African Trypanosomiasis and explored inhibitors for FLT3-ITD, including those resistant to existing therapies. His publications also detail the discovery of orally active selective aurora kinase B inhibitors.
Naresh collaborates with researchers at the University of Arkansas for Medical Sciences, including Xiuqi Wang and Phuc Tran. His scholarship metrics include an h-index of 13, with 30 total publications and 563 citations. He is actively publishing, with his most recent work in 2025.
Metrics
- h-index: 13
- Publications: 30
- Citations: 577
Selected Publications
-
Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor (2025)
-
An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L (2023)
-
Abstract 5155: Orally bioavailable aurora-kinase B inhibitor (MK7) as a potential therapeutic approach in multiple myeloma (2020)
-
Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation (2020)
-
Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression (2020)
-
Targeting Aurora-kinase B with the novel Aurora Kinase B inhibitor MK7 in multiple myeloma (2019)
-
Use of Imidazo[1,2‐<i>a</i>]pyridine as a Carbonyl Surrogate in a Mannich‐Like, Catalyst Free, One‐Pot Reaction (2019)
-
Catalyst free, C-3 functionalization of imidazo[1,2- <i>a</i> ]pyridines to rapidly access new chemical space for drug discovery efforts (2018)
-
Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application (2018)
-
Selective, C-3 Friedel-Crafts acylation to generate functionally diverse, acetylated Imidazo[1,2-a]pyridine derivatives (2018)
-
Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT (2018)
Collaboration Network
Top Collaborators
Xiuqi Wang
University of Arkansas for Medical Sciences
2 shared publications
In database
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Phuc Tran
University of Arkansas for Medical Sciences
2 shared publications
In database
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Hongyu Li
The University of Texas Health Science Center at San Antonio (US)
2 shared publications
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Rosa Anna DeFilippis
University of California, San Francisco (US)
1 shared publication
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
Tsigereda Weldemichael
University of Arkansas for Medical Sciences
1 shared publication
In database
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
Yuet‐Kin Leung
University of Arkansas for Medical Sciences
1 shared publication
In database
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
Neil P. Shah
University of California, San Francisco (US)
1 shared publication
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
Marialuisa Moccia
University of Naples Federico II (IT)
1 shared publication
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Annalisa Brescia
University of Naples Federico II (IT)
1 shared publication
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Giorgia Federico
University of Naples Federico II (IT)
1 shared publication
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Zhenyu Wang
The University of Texas Health Science Center at San Antonio (US)
1 shared publication
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Min Yang
The University of Texas Health Science Center at San Antonio (US)
1 shared publication
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Minmin Wang
The University of Texas Health Science Center at San Antonio (US)
1 shared publication
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Baha’a Jabali
University of Arkansas for Medical Sciences
1 shared publication
In database
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Wei Yan
University of Arkansas for Medical Sciences (US)
1 shared publication
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Similar Researchers
Based on overlapping research topics
Alicja Urbaniak
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Drug Delivery Systems
Brendan Frett
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Protein Kinase Inhibitors
Disease Mechanisms Research
Xiuqi Wang
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Drug Delivery Systems
C-K Lee
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Disease Mechanisms Research
Molecular Biology Techniques and Applications
Hubay Ca
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Disease Mechanisms Research
Molecular Biology Techniques and Applications
Fengping Lv
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Molecular Biology Techniques and Applications